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Metabolic labeling probes for interrogation of the
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Bacterial infections are still one of the leading causes of death worldwide; despite the near-ubiquitous
availability of antibiotics. With antibiotic resistance on the rise, there is an urgent need for novel classes of
antibiotic drugs. One particularly troublesome class of bacteria are those that have evolved highly effica-
cious mechanisms for surviving inside the host. These contribute to their virulence by immune evasion,
and make them harder to treat with antibiotics due to their residence inside intracellular membrane-
limited compartments. This has sparked the development of new chemical reporter molecules and
bioorthogonal probes that can be metabolically incorporated into bacteria to provide insights into their
activity status. In this review, we provide an overview of several classes of metabolic labeling probes
capable of targeting either the peptidoglycan cell wall, the mycomembrane of mycobacteria and coryne-
bacteria, or specific bacterial proteins. In addition, we highlight several important insights that have been
made using these metabolic labeling probes.
Introduction
Despite the near-ubiquity of antibiotics in modern times, bac-
terial infections are still among the leading causes of death
globally.1 Overuse of antibiotics in high-income countries has
contributed to an evolutionary selection pressure that is
driving antibiotic resistance.2 New antibiotic resistance mecha-
nisms are rapidly emerging,3 resulting in a staggering increase
in multi-drug resistant (MDR), extensive drug resistant (XDR)
and pan-drug resistant (PDR) strains.4 At the same time, the
development of novel classes of antibiotics has been extremely
slow, with only two new classes of broad-spectrum antibiotics
introduced to the clinic since 1962.5,6 Development of anti-
biotics for a certain class of pathogenic bacteria has been par-
ticularly difficult: the intracellular bacteria. Intracellular bac-
teria reside inside host cells, where they can evade immune
detection and persist for months or even years in a dormant
state.7,8 In order for an antibiotic to be active against infec-
tions caused by intracellular bacteria, the drug not only has to
cross the bacterial cell envelope but also the host cell mem-
brane. The study of (obligate) intracellular pathogens is
further complicated by the fact that they are often difficult to
culture in vitro.9,10 In light of these challenges, novel anti-
biotics against intracellular bacteria are much needed, as the
disease burden from these species is very high.
The deadliest bacterial species is arguably Mycobacterium
tuberculosis (Mtb), a facultative intracellular bacterium that is
the major cause of tuberculosis (TB). This pathogen is respon-
sible for approximately 2 million deaths annually11 and anti-
biotic-resistant strains are continually emerging. Treating
infections due to Mtb is made difficult by the heterogeneity in
its intracellular life cycle: after infecting macrophages it
diverges into fast and very slow-growing forms.12,13 The slow
growing form is generally hard to treat with conventional anti-
biotics such as those that target the nascent cell wall of the
dividing bacteria.14–20 As a result, TB is typically treated with a
complex cocktails of antibiotics that need to be taken for long
periods of time. Addressing infections due to MDR Mtb is even
more challenging requiring antibiotic treatment courses of up
to 2 years (often with severe side-effects).21 One new therapy –
the first in many years – was recently approved for drug-resist-
ant forms of Mtb: pretomanid in combination with bedaqui-
line and linezolid. Whilst this is laudable – as is the clinical
development of other Mtb active agents – the demand for new
treatments for Mtb and other intracellular pathogens currently
far outstrips supply.22 Mtb is not the only intracellular patho-
gen causative of high-mortality/morbidity disease. Other intra-
cellular pathogens of clinical concern include Salmonella enter-
ica, Yersinia pestis, Chlamydia trachomatis, Listeria monocyto-
genes and Coxiella burnetii to name but a few.23 Whilst not dis-†Both authors contributed equally.
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playing quite the same nefariousness as Mtb, these organisms
are associated with a host of pathologies ranging from inferti-
lity to increased risk of bowel cancer.24,25 While these patho-
gens can largely still be controlled with available antibiotics,
the increased emergence of resistance threatens our continued
ability to do so and paints a bleak future.26
Bacterial pathogens have acquired highly effective mecha-
nisms for infecting- and surviving inside hosts. These mecha-
nisms lead to increased virulence and persistence within the
host environment, along with suppression of the host immune
system.27 Due to their importance for bacterial cell viability
and infectivity inside the host, bacterial defense mechanisms
at the host–pathogen interface are a promising target for novel
antibiotics.28,29 Thus, effective chemical tools to study the
host–pathogen interface at the molecular level are of para-
mount importance in deepening our understanding of the
relationship between the fundamental biochemistry of the
host–pathogen and their virulence. This in turn can provide
new information in the fight against antibiotic resistance. To
provide clinically significant data, these chemical tools must
be useable in cell culture and in vivo in pathogenic bacteria.
Moreover, the cellular processes they report on must be rele-
vant to bacterial cell survival and/or virulence.
Recently, novel chemical probes and approaches have been
developed that allow for the profiling of various metabolic pro-
cesses as well as in cell cell wall and protein labeling. In meta-
bolic profiling a chemical probe is exogenously supplied to an
organism, which subsequently incorporates the chemical
probe into its cellular architecture by means of endogenous
enzymes. Novel chemical probes have been developed that
carry fluorescent dyes allowing for facile, one-step metabolic
labeling of bacterial structures of interest such as the peptido-
glycan (PG) cell wall,30,31 or the mycomembrane of
corynebacteria.32,33 Moreover, the introduction of bioorthogo-
nal chemistry has furthered the field by allowing for chemical
reactions to be performed inside the crowded environment of
the bacterial cell.34 Bioorthogonal groups are by definition
non-reactive, or orthogonal, to their biological environment,
but highly reactive towards their bioorthogonal reaction
partner.35 Moreover, bioorthogonal groups such azides or
alkynes can be readily introduced into common bacterial
metabolites with minimal perturbation of biological function.
After metabolic incorporation into bacteria, bioorthogonal
probes can be reacted with reporter molecules carrying a com-
plimentary bioorthogonal group. Such reporters include fluoro-
phores that allow for the visualization of bacterial biomolecules
of interest or affinity tags to facilitate their enrichment. As such,
bioorthogonal chemistry has driven advancements in two-step
metabolic labeling approaches for host–pathogen interaction
studies. As a whole, metabolic labeling in bacteria, in one step
or two steps, has shed a light on previously uncharacterized bac-
terial cell processes, making it a valuable tool in the search for
novel targets for antibiotic drug development.
Here, we review recent developments in the field of meta-
bolic labeling in the context of the host–pathogen interface.
We cover the initial discoveries of several chemical probes and
labeling strategies and the subsequent improvements made to
these probes and labeling strategies while also highlighting
several examples of important findings achieved using these
methods. Specifically, we highlight the use of D-amino acids
(DAAs) for metabolic labeling of PG in the bacterial cell wall
and the labeling of the mycomembrane of corynebacteria
using trehalose-analogues. Also covered is the use of bioortho-
gonal non-canonical amino acid tagging for the labeling of
new protein synthesis in bacteria and the application of so-
called activity based probes that target enzyme activities
specific to the bacterial pathogen of interest.
Metabolic labeling of peptidoglycan
Peptidoglycan (PG) is the major constituent of the bacterial
cell wall. PG consists of linear glycan strands that are cross-
linked through short peptides, creating a dense macromolecu-
lar network that is vital to bacterial survival. The bacterial cell
wall provides structural integrity for the cell and protects it
against the osmotic pressure established by high intracellular
concentrations of proteins and other biomolecules.36 The PG
cell wall also functions as an anchor for important macro-
molecules of the cell envelope, such as teichoic acids,37 and
Braun’s lipoprotein.38 Due to its vital role in bacterial survival,
relative accessibility at the outside of the cell, and absence in
eukaryotic cells, PG biosynthesis is a prime target for anti-
biotics.39 Many widely used antibiotics including the β-lactams
exemplified by penicillin,40 glycopeptides such as vancomy-
cin,41 and the lipopeptide bacitracin42 function by inhibiting
various aspects of bacterial cell wall biosynthesis. However,
due to misuse and overuse, bacteria are acquiring resistance
against these antibiotics at an alarming rate.5,43 Nonetheless,
the bacterial cell wall remains a very promising target for the
development of novel antibiotics.
PG metabolism has been studied using various methods,
such as metabolic labeling with radioprobes.44 Other methods
include labeling of the bacterial cell wall using fluorescently
tagged antibiotics45,46 as well as by the incorporation of a
fluorescently labeled tripeptide into the cell wall by exploiting
the PG recycling machinery of Escherichia coli (E. coli).47 These
techniques have multiple limitations: (1) labeling techniques
that are dependent on the PG recycling pathway of E. coli can
only be used to study this specific organism; (2) radiolabeling
of PG is known to be a very laborious and technically complex
technique; (3) labeling the bacterial cell wall using fluores-
cently tagged antibiotics is limited to bacterial species with an
accessible cell wall and enzyme machinery tolerant to these
large pendant fluorophores; and (4) the use of fluorescently
tagged antibiotics has an inhibitory effect on bacterial cell
growth, thereby limiting their use.
Recently, metabolic labeling of PG using new D-amino acid
(DAA) analogues has led to significant advancements in the
understanding of cell wall biosynthesis and recycling of PG.
Whereas nearly all life forms use exclusively L-amino acids,
most bacteria also use DAAs, which are incorporated into the
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PG cell wall.48 D-Alanine and D-glutamic acid are the DAAs that
are most often incorporated into PG and can thus be found in
the cell wall of nearly all bacteria.48 Interestingly, studies have
shown that the biosynthetic machinery involved in PG syn-
thesis is highly tolerant to a variety of different DAAs.49,50 This
phenomenon has been exploited to incorporate DAAs and ana-
logues thereof, to act as reporter molecules (one-step meta-
bolic PG labeling) or as chemical handles for the conjugation
of reporter molecules (two-step metabolic PG labeling).
Kuru et al.30 were the first to employ fluorescent D-amino
acids (FDAAs) for one-step PG labeling and imaging of bac-
terial cell walls in live cells. Starting from the D-amino acids
3-amino-D-alanine and D-lysine, they reacted reporter mole-
cules 7-hydroxycoumarin-3-carboxylic acid (HCC), 4-chloro-7-
nitrobenzofurazan (NBD), fluorescein and carboxytetramethyl-
rhodamine (TAMRA) to synthesize a variety of fluorescent
amino acids, such as HADA, NADA, FDL and TDL (Fig. 1).30
Subsequently, they succeeded in labeling a wide range of
Gram-negative and Gram-positive bacteria, including, but not
limited to, E. coli, Staphylococcus aureus and Bacillus subtilis,
and showed that these FDAAs were selectively incorporated
into the bacterial cell wall. In B. subtilis, they showed that
these FDAAs were incorporated exclusively into PG and not
into teichoic acids; which also contain D-alanine residues.30
Because of their broad species applicability and excellent
selectivity for PG, FDAAs have been used to study cell wall syn-
thesis and its role in pathogenesis,51–59 and to establish the
presence of PG in many bacterial species.60–62 An interesting
application of FDAAs is the construction of so-called ‘virtual
time-lapse’ images of PG synthesis in individual organisms. By
sequentially adding FDAAs with different spectral properties,
the growing PG layer can be sequentially labeled with multiple,
differently colored FDAAs. This creates a multi-colored image
where each color represents the location and amount of PG
that is synthesized during the time in which FDAA was
added.30,63
FDAAs owe their broad applicability partially to their low
molecular weight; labeling of the Gram-negative bacterial cell
wall requires passage through the outer membrane, which is
markedly less permeable to molecules over a molecular weight
of ∼600 Da, such as antibiotics.64 Indeed, when Hsu et al.65
compared the labeling of E. coli with FDAAs with molecular
weights between 300–700 Da, they found that FDAAs over a
molecular weight of ∼500 Da have reduced access to the E. coli
periplasm and cytoplasm and label the cell wall less efficiently.
Today, the available toolkit of FDAAs covers the whole visible
spectrum, from violet to far-red, providing many options for
PG imaging in real time. Amongst these are FDAAs that are
compatible with stochastic optical reconstruction microscopy
(STORM), such as Cy3B and Atto 488, allowing imaging of PG
nanostructures with far better spatial resolution.65
Improvements to other FDAAs include increased water solubi-
lity, increased photostability, and the possibility to excite with
far-red light, reducing the phototoxic burden on the bacteria
that is being probed. In conclusion, FDAA labeling is an excel-
lent analysis technique to study the bacterial cell wall because
of its selectivity for bacterial PG, it’s relative experimental sim-
plicity, and the ubiquity of DAAs in the cell walls of all bac-
terial taxa. Moreover, FDAAs only label nascent PG and are
therefore an ideal tool to study spatial and temporal aspects of
PG synthesis. The expansion of the FDAA toolkit into probes
that are suitable for STORM has improved the spatial resolu-
tion that can be attained with FDAA labeling and cements the
relevance of this technique for the study of the bacterial cell
wall.65 Notably, however, FDAAs have not yet been applied to
the imaging of intracellular pathogenic bacteria.
One downside of the FDAA-approach is that these probes
are only incorporated into PG via the extracellular pathways
reliant on the D,D- and L,D-transpeptidases, and are therefore
not tolerated by the D-alanine racemase (Alr) and the UDP-N-
acetylmuramoyl-tripeptide-D-alanyl-D-alanine ligase
(MurF).62,66 These steps of the pathway in most species can,
however, be labeled using a two-step labeling approach. The
approach is based on metabolic incorporation of a D-amino
acid equipped with a specific chemical handle, which, once
incorporated into the PG network, can be labeled using a
reporter molecule that is reactive to the handle. Two-step PG
labeling has a lower risk of causing biological perturbation
than one-step PG labeling, as the chemical handle is usually
much smaller than the probes used in one-step PG labeling.
Presently, bioorthogonal groups are commonly used as chemi-
cal handles in two-step PG labeling, because of their high reac-
tivity towards their bioorthogonal reaction partners and their
inertness towards biomolecules.34 PG labeling has been per-
formed using D-cysteine as a chemical handle, effectively incor-
porating thiol groups into the cell wall for coupling to thiol-
reactive reporter molecules.67 But, reporter molecules that
target D-cysteine do not selectively label PG, as they are also
reactive to L-cysteine residues in cellular proteins. To overcome
such limitations, the introduction of D-amino acids containing
bioorthogonal groups such as azides, alkynes, and nitrones
allows for highly selective two-step metabolic labeling of PG.68
Kuru et al.30 and Siegrist et al.31 independently reported the
use of DAAs containing bioorthogonal groups for PG labeling:
R-propargylglycine (also known as ethynyl-D-alanine, EDA) and
2-amino-3-azidopropanoic acid (commonly known as azido-D-
alanine, ADA) (Fig. 1). Kuru et al. validated the concept of
bioorthogonal two-step metabolic PG labeling by labeling both
B. subtilis and E. coli cells in vitro with EDA and ADA.30
Expanding on this work, Siegrist et al. showed that Listeria
monocytogenes and Mtb could be efficiently labeled by EDA and
ADA, in vitro and inside infected J774 macrophages. Notably,
this work also demonstrated that macrophages take up
sufficient EDA for effective labeling of intracellular bacteria
without any apparent toxicity to either the macrophages or
bacteria, highlighting the potential of two-step metabolic DAA
labeling for cell culture-based applications.17 Combining the
promiscuity of EDA labeling with the selectivity of RADA label-
ing, García-Heredia et al. showed that PG repair also occurs
away from the sites of de novo PG synthesis in various myco-
bacterial species.66 Since then, Pidgeon et al. also reported
probes specific for the L,D-transpeptidase to provide further
Review Organic & Biomolecular Chemistry

































































































tools to study bacterial cell wall synthesis. The possibility of
applying these probes to the study of the intracellular lifecycle
of pathogens offers a tantalizing opportunity as a tool in the
development of drugs against such pathogens.69
The bioorthogonal toolkit for metabolic labeling of PG was
further expanded by Shieh et al.70 They synthesized D-amino
acids equipped with the strained cyclooctyne and bicyclono-
nyne (BCN) moieties (Fig. 1), for copper-free, strain-promoted
alkyne–azide “click” (SPAAC) reactions. Furthermore, they syn-
thesized near-infrared (NIR) azide-functionalized fluorogenic
Si-rhodamine dyes whose fluorescence quantum yield greatly
increases upon reaction with alkynes. These NIR fluorogenic
dyes are very useful for in vivo imaging as near infrared light
penetrates deeper through tissue than higher wavelength light
and no washing of excess dye is required as the dye becomes
vastly more fluorescent upon reaction. The Pezacki group
added an additional bioorthogonal reaction to the labeling
repertoire by designing nitrone D-amino acids that readily
Fig. 1 (A) Schematic overview of the labeling approaches; (B) D-amino acid probes for metabolic labeling of peptidoglycan (PG); (C) click-reactive
muramic acid and acetyl-CoA analogues.
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undergo reactions with strained alkynes in a strain-promoted
alkyne-nitrone cycloaddition (SPANC) reaction (Fig. 1).68,71
Metabolic incorporation of D-amino acid probes is well tol-
erated in most bacteria, with notable exceptions. For instance,
the intracellular bacterium Chlamydia trachomatis required
additional reagents to enable PG labeling. While circumstan-
tial evidence for the existence of a PG containing cell wall in
C. trachomatis had existed for decades,72,73 until recently no
one had conclusively isolated or characterized PG from this
bacterium.74,75 This resulted in a discrepancy called the
‘Chlamydial Anomaly’, where no PG was observed, yet the
pathogen was sensitive to PG-targeting antibiotics.76,77 To
address the matter Liechti et al. set out to conclusively estab-
lish the presence of PG in C. trachomatis by labeling with the
D-amino acid probe EDA, but found that EDA failed to label
the bacteria.62 They hypothesized that this was because chla-
mydial PG synthesis enzymes could not accommodate EDA,
but that they might accommodate modified D-alanine dimers
wherein one of the two amino acids was EDA (EDA-DA).
Indeed, after incubating the bacteria with the alkyne contain-
ing EDA-DA dipeptide, they were subsequently able to label
C. trachomatis with Alexa Fluor 488 azide. Interestingly, no
labeling was detected when using the dipeptide analogue
bearing the bioorthogonal modification on the C-terminal
D-alanine residue (i.e. DA-EDA). The authors reasoned that the
lack of labeling was due to removal of the C-terminal D-alanine
residue in either transpeptidation or carboxypeptidation reac-
tions. The work of Liechti et al. shows that labeling of PG in
some bacteria may require modified D-amino acid probes, but
also highlights the versatility of D-amino acid labeling for the
detection and study of bacterial PG.
In addition to the use of unnatural D-amino acids, strategies
based on other building blocks have been developed to probe
PG assembly in bacteria. In this regard, Grimes and coworkers
designed metabolic probes based on N-acetyl muramic acid
(MurNAc) that allowed for labeling of the carbohydrate moiety
of PG.78,79 Although labeling of PG with D-amino acids ana-
logues is a powerful and versatile method, there are several
benefits to labeling this carbohydrate moiety: firstly, D-alanine
residues of the PG stem peptide can be removed by transpepti-
dation and carboxypeptidation reactions, which may decrease
the probe’s lifetime, whereas the carbohydrate backbone of PG
is not subject to remodeling. Secondly, MurNAc is a superior
probe for de novo PG synthesis, as it is only incorporated in
newly synthesized PG, while D-alanine probes can also be
incorporated into mature PG by exchange reactions.50,80,81
Finally, MurNAc binding to Nod-like receptors (NLRs) is
involved in innate immune activation,82 while D-alanine resi-
dues are not involved in immune activation, making MurNAc
analogues more suitable for probing immune activation by PG.
Metabolic labeling of the carbohydrate moiety in PG was first
achieved by Liang et al. using MurNAc analogues with azido-
and alkyne modifications at the 2-N acetyl position (Fig. 1).78
In some Gram-negative bacteria, including, amongst others,
Pseudomonas putida, MurNAc can be recycled to uridine dipho-
sphate-MurNAc (UDP-MurNAc) by enzymes AmgK and MurU
and subsequently incorporated into newly synthesized PG.83
Interestingly, Liang et al. showed that both E. coli and
B. subtilis could incorporate MurNAc analogues into de novo
synthesized PG after transfection with a vector for P. putida
AmgK and MurU.78 Their results suggest that metabolic
MurNAc labeling could be applied to a wide range of bacteria,
both Gram-negative and Gram-positive, if transfected with
amgK and murU. Metabolic MurNAc labeling of most bacteria
does, however, require genetic modification of the bacteria
and is limited to bacteria in which amgK and murU can be
introduced, limiting the practical use of this particular meta-
bolic labeling technique.
Building on these approaches, Wang et al. recently reported
an elegant method for post-synthetic, metabolic labeling of
the PG carbohydrate backbone.79 Their technique exploits the
function of the bacterial enzyme peptidoglycan
O-acetyltransferase B (PatB), which uses acetyl-CoA as an acetyl
donor to O-acetylate the 6′ hydroxyl group of MurNAc residues
in the carbohydrate moiety of PG.84 Post-synthetic
O-acetylation of PG occurs in many intracellular pathogenic
bacteria, such as Neisseria meningitidis, Neisseria gonorrheae
and Staphylococcus aureus,85–87 where it contributes to bac-
terial virulence by providing resistance against PG degradation
by the antimicrobial enzyme lysozyme.88 Wang et al. hypoth-
esized that bioorthogonal groups could be introduced into PG
post-synthetically by feeding azide- (SNAz) or alkyne- (SNAk)
functionalized acetyl-CoA analogues (Fig. 1). They found that
PatB efficiently O-acetylates PG in B. subtilis when supplied
with SNAz or SNAk and in doing so enabled visualization of
the incorporated probes by reaction with fluorescent dyes car-
rying complementary bioorthogonal groups.79 Interestingly,
they also showed that the artificially O-acylated B. subtilis was,
at least partially, protected from degradation by lysozyme.
Metabolic labeling of the
mycomembrane using trehalose
analogues
The mycobacterial cell wall contains an outer membrane – the
mycomembrane (MM) – that lends itself well to selective label-
ing. It consists of long chain (C60–C90) mycolic acids that are
covalently linked to the cell wall’s PG layer through highly
branched polysaccharides called arabinogalactan (AG).89,90
Components of the MM are important for mycobacterial cell
survival; for example, blocking the biosynthesis of the non-
mammalian disaccharide trehalose, a key component of the
MM glycolipids trehalose dimycolate (TDM) and trehalose
monomycolate (TMM), reduces cell viability and induces
growth defects.91,92 TMM is a modulator of MM biosynthesis84
and a precursor to TDM, which promotes virulence and survi-
val in host macrophages.93 Since trehalose metabolism is vital
for mycobacterial cell viability and is not found in mammalian
cells, its biosynthetic pathway makes an excellent target for the
development of novel antibiotics against Mtb. Moreover, since
Review Organic & Biomolecular Chemistry

































































































trehalose is exclusively found in members of the suborder of
Corynebacterineae, which does not include canonical Gram-
negative or Gram-positive bacteria, it opens up the possibility
to use metabolic labeling with trehalose-probes for clinical
diagnosis of Mtb.
Clinical diagnosis of Mtb in high-burden, developing
countries is currently performed using either the Ziehl–
Neelsen test or the Auramine Truant stain, both of which are
only moderately reliable.86 Furthermore, these diagnostic tests
also do not discriminate between live or dead Mtb cells and
thus cannot be used by physicians to determine treatment
efficacy.94 Thus, novel, Mtb-specific diagnostic tools are
required to improve TB diagnosis efficacy. Metabolic labeling
with trehalose analogues has shown promise as a novel diag-
nostic approach for the rapid detection of Mtb infection.
Trehalose, in the form of TMM and TDM, is anchored non-co-
valently to the mycobacterial cell wall. Trehalose is synthesized
and esterified to form TMM in the cytosol, after which TMM is
transported to the periplasm.95 Once in the periplasm, the
mycolyltransferase complex antigen 85 (Ag85) transfers myco-
late from TMM to AG, to form a network of covalent mycolates
that form the foundation of the MM, or to another molecule of
TMM, forming TDM.96–98 In both cases, a molecule of treha-
lose is regained, which is recycled by active transport into the
cytosol by the trehalose-specific transporter SugABCLpqY.99
Based on analysis of the trehalose/Ag85 co-crystal structure,
Backus et al.32 hypothesized that trehalose could be modified
with functional groups without affecting substrate activity for
Ag85, exploiting a promiscuity that is similar to that of
D-alanine metabolism. They synthesized various trehalose-ana-
logues, including fluorescein isothiocyanate (FITC)-trehalose
(FITC-Tre, Fig. 2), and tested their ability to label pathogenic
Mtb using a one-step labeling method. FITC-trehalose was
efficiently incorporated into growing Mtb mycomembranes by
Ag85 in vitro and exclusively labeled live Mtb cells; heat-killed
Mtb cells were not labeled, nor were cells of the Gram-negative
pathogens Pseudomonas aeruginosa and Haemophilus influenza
or Gram-positive Staphylococcus aureus.32 FITC-Tre could even
be incorporated into Mtb inside macrophages; macrophages
were infected with Mtb and successfully labeled with FITC-Tre.
Backus et al. also demonstrated that Ag85 enzymes tolerate
a surprisingly wide range of substrate modifications.
Moreover, their work demonstrates that the Ag85 pathway can
be hijacked to incorporate exogenous trehalose into TMM and,
subsequently, into the MM. They also speculate that, given the
conserved nature of Ag85 amongst mycobacteria, the FITC-tre-
halose probe could presumably label other mycobacterial
species equally as well as Mtb. However, Rodriguez-Rivera et al.
found that FITC-trehalose labels other mycobacterial with
poor efficiency and does not label corynebacteria at a detect-
able level at all.100 SAR studies showed that removal of an
anomeric methyl group significantly increased labeling
efficiency amongst myco- and corynebacteria, as did reposi-
tioning of the FITC functionality on the trehalose scaffold.
Rodriguez-Rivera et al. applied metabolic trehalose labeling to
assess the influence of ethambutol treatment on mycomem-
brane fluidity using fluorescence recovery after photobleaching
(FRAP) experiments. They showed that ethambutol can
increase MM fluidity at sub-inhibitory concentrations, thereby
enhancing antibiotic drug accessibility.100
One-step metabolic labeling is an excellent method for
metabolic incorporation of trehalose analogues into the myco-
membrane via extracellular incorporation by the Ag85
complex. However, an important aspect of trehalose metab-
Fig. 2 Fluorescent and fluorogenic trehalose analogues for labeling of the mycomembrane.
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olism occurs intracellularly, where trehalose is formed and
subsequently incorporated into various metabolites, which
together constitute the ‘trehalome’.33 The importance of treha-
lose for bacterial survival calls for chemical probes that can
provide insight into intracellular trehalose metabolism. Swarts
et al.33 hypothesized that the trehalose-recycling pathway
could be hijacked to actively transport azido-trehalose ana-
logues into the mycobacterial cytosol through the trehalose-
specific transporter SugABCLpqY, after which the trehalose-
analogue would be incorporated into the ‘trehalome’ and sub-
sequently labeled with azide-reactive reporter molecules.
Trehalose-analogues with azido-groups (TreAz analogues) at
the 2-, 3-, 4- or 6-position (Fig. 2) were added to a culture of
Mycobacterium smegmatis, a non-pathogenic Mycobacterium
that is frequently used as a model organism for Mtb, and then
exposed to a fluorescent dye coupled to a cyclooctyne group
leading to labeling via a strain-promoted [3 + 2] cycloaddition.
They found that the TreAz analogues labeled M. smegmatis
efficiently and that the route of trehalose incorporation was
dependent on the structure of the TreAz analogue; 2-, 4- and
6-TreAz were incorporated via the recycling pathway, while
3-TreAz was incorporated only extracellularly by Ag85. This
incorporation was also possible for pathogenic Mtb and
Mycobacterium bovis. The recent development of chemoenzy-
matic routes towards unnatural trehalose analogues is
expected to expand the application of this method by facilitat-
ing access to the new analogues.101
Two-step metabolic labeling with trehalose analogues has
also been applied to study mycolation of AG and O-mycolated
proteins that are found in the MM. The Swarts group hypoth-
esized103 that the substrate specificity of Ag85 as a mycolyl-
transferase would extend to a 6-heptynoyl trehalose analogue
(O-AlkTMM, Fig. 2), based on previously reported Ag85 activity
studies.32,102 They hypothesized that O-AlkTMM could be
taken up into the periplasm, where Ag85 would transfer the
6-heptynoyl group to mycolyl acceptors such as AG and
O-mycolated proteins.103,104 Subsequent reaction with alkyne-
reactive reporter molecules would allow for enrichment or
visualization of mycolated targets. Foley et al.103 reported on
the synthesis of O-AlkTMM and showed that O-AlkTMM effec-
tively labels mycobacterial AG. Similar to TreAz analogues,
O-AlkTMM selectively labels cell walls of mycobacteria and cor-
ynebacteria without labeling canonical Gram-negative and
Gram-positive bacteria. In contrast to TreAz analogues, meta-
bolic labeling with O-AlkTMM also provides the means to
directly incorporate labels during the synthesis of AG mycolate
(AGM), which is an essential component of the mycobacterial
cell wall. O-Mycolation of proteins has only recently been dis-
covered as a post-translational protein modification in coryne-
bacteria.105 Notably, O-acylation of bacterial proteins was
unheard of prior to the discovery of O-mycolated proteins,
making it an intriguing phenomenon and worthy of further
study. Using the O-AlkTMM probe, Kavunja et al.104 were able
to label multiple O-mycolation target proteins in
Corynebacterium glutamicum. Next, they visualized them with
an in-gel fluorescence assay, by means of the well-established
copper(I)-catalyzed alkyne–azide cycloaddition (CuAAC) click
reaction with Alexa Fluor 488 azide. Their study uncovered
multiple novel O-mycolated proteins and revealed that proteins
can carry more than one O-mycolate group, highlighting the
utility of the O-AlkTMM probe for studies into the ‘O-mycoloy-
lome’. Much remains to be discovered about bacterial protein
O-mycolation and the O-AlkTMM probe has proven to be a
highly valuable tool for such O-mycolation studies. Taken
together, the aforementioned investigations show the potential
of trehalose analogues for studies into trehalose- and myco-
loyl-metabolism. The same group recently expanded the
bioorthogonal TMM library to include trans-cyclooctene TMM
analogues reactive in an inverse electron-demand Diels–Alder
ligation reaction.106
Recently, various trehalose analogues have emerged as
novel potential point-of-care diagnostic tools for Mtb. This is a
large unmet clinical need, as the current diagnostic methods
are notoriously unreliable.107 Rundell et al.108 took the first
steps towards synthesis of an 18F-labeled trehalose analogue
that would facilitate targeted positron emission tomography
(PET) imaging of patients lungs for quick diagnosis of TB
infections. However, this approach requires advanced equip-
ment for diagnosis – infrastructure often absent at remote
diagnostic sites. To provide a facile low-tech Mtb-detection
test, Kamariza et al.109 developed a solvatochromic trehalose
probe (DMN-Tre), consisting of a trehalose-conjugated fluo-
rescent dye, 4-N,N-dimethylamino-1,8-naphthalimide (DMN)
(Fig. 2), that dramatically increases in fluorescence upon tran-
sition from a hydrophilic to a hydrophobic environment. The
authors showed that the solvatochromic nature of DMN
allowed for no-wash labeling of Mtb, since DMN-Tre should
only become fluorescent once incorporated into the hydro-
phobic environment of the MM. DMN-Tre could indeed be
used for efficient no-wash labeling of Mtb cells, even in
sputum samples from TB-positive patients. This probe was
further used for high-content image-based screening of the
effect of various drugs on intracellular Mtb.110 Recently, new
solvochromatic trehalose probes based on 3-hydroxychromone
fluorophores (3HC, Fig. 2) were reported that show a 10-fold
increase in fluorescence enhancement compared to DMN.
This allowed the detection of Mtb cells within 10 minutes of
treatment and may well represent a major step towards on-site
testing for Mtb infection.111
Hodges et al. recently reported the use of a different strategy
for fluorogenic Mtb cell wall detection. Their approach
employs a trehalose variant dubbed “quencher-trehalose-
fluorophore” (QTF, Fig. 2) consisting of a lipid-BODIPY con-
struct and a DABCYL quencher attached to a trehalose
scaffold.112 Esterase Ag85 cleaves the lipid-fluorophore from
the quencher-trehalose, leading to enhancement (turn-on) of
fluorescence (Fig. 2). Finally, the Swarts-group recently
reported a similar approach, in which cleavage of a quencher
group from a construct containing fluorescein and a DABCYL
quencher by the mycomembrane remodeling hydrolase Tdmh,
led to a the enhancement of green fluorescence.113 One down-
side to all these probes is that they exclusively label metaboli-
Review Organic & Biomolecular Chemistry

































































































cally active cells. As such, they can only be used to diagnose
dividing Mtb and monitor treatment efficacy. The metaboli-
cally dormant forms of Mtb, however, remain undetected by
these technologies. There remains an urgent and unmet need
for the development of probes for this subclass of Mtb.
Proteome labeling with BIOORTHOGONAL amino ACIDs
The methionine tRNA/tRNA synthetase pair of many species
are rather promiscuous. At the turn of the millennium, the
Tirrell and Bertozzi groups were the first to exploit this promis-
cuity to introduce bioorthogonal groups into bacterially
expressed proteins and label these using click reactions.114
This technique was later applied by the Tirrell-lab to the pan-
proteome Met-labeling of whole cells. The approach, latter
dubbed bioorthogonal non-canonical amino acid tagging
(BONCAT),115 has subsequently been used for the enrichment,
identification, and visualization of exclusively nascent pro-
teins, thus reducing the complexity of proteomic analysis of a
given sample.116 Moreover, pulse-labeling with BONCAT
probes allows for analysis of changes in protein production in
response to internal and external cues.115 With regards to the
study of intracellular pathogens, two BONCAT-based
approaches have been taken. Those reliant on the hijacking of
existing tRNA/synthetase pairs, and those that genetically
incorporate new tRNA/synthetase pairs. Both approaches have
been used extensively to interrogate pathogen’s protein
expression at the host–pathogen interface.
The first approach, which relies on the promiscuity of the
methionine tRNA and its synthetase, have shown that meth-
ionine analogues containing alkene-,117–120 alkyne-117,121 and
azido-114 functionalities can be accepted substrates by the
methionyl-tRNA synthetase (MetRS) in a variety of pro- and
eukaryotes.122 Care has to be taken when incorporating these
amino acids into new species, as the speed of protein synthesis
and cell division can be altered by the presence of such un-
natural amino acids, as demonstrated by homopropargylgly-
cine (Hpg, Fig. 3) which shows toxicity towards certain bacteria
at higher incubation rates, whereas azidohomoalanine does
not (Aha, Fig. 3).123 The advantage of this approach is that it
provides a facile way to image only the proteome of an intra-
cellular pathogen after uptake by a host cell, without any need
for further genetic modification of the species. Reacting these
proteins with a clickable biotin- or FLAG-tag can also enable
the enrichment of these target proteins for mass spec-
trometry.116 We ourselves have used this strategy to incorpor-
ate Aha or Hpg into E. coli ex vivo and then co-incubated these
bacteria with mouse bone marrow-derived cells (BMDCs) to
visualize bacterial cell degradation in situ.124 For this we used
correlative light-electron microscopy (CLEM) imaging, to
provide ultrastructural content of the degrading E. coli cells
within BMDC phagosomes. We have also translated the tech-
nique to allow super-resolution correlative light-electron
microscopy (STORM-CLEM) of pathogens in BMDCs to show
the durability of Salmonella bacteria inside the host cell
vacuole.123 Recently, we also combined the BONCAT labeling
of the Mtb proteome with the labeling of its PG layer through
the use of EDA-labeling with correlative imaging, showing that
multiple click reactions can be performed on pathogens simul-
taneously. We used this approach to assess the heterogeneous
effect of various antibiotics on intracellular Mtb (see Fig. 4 for
an example image).125
Approaches that allow expansion of the genetic code of
pathogens have also become powerful tools to study host–
pathogen interactions. For example, Ngo et al.126 devised a
new BONCAT-like strategy that involved genetically modifying
the cell type of interest to enable incorporation of NCAA for
this cell type only. For this strategy, a mutant MetRS
(NLL-MetRS) was developed that can append the NCAA azido-
norleucine (ANL; Fig. 3) to endogenous tRNA.127 To achieve
cell type selective protein labeling with bioorthogonal handles,
the cell type of interest is transfected with the NLL-MetRS
gene, enabling this cell type to incorporate ANL into newly syn-
thesized proteins. ANL is not compatible with endogenous
MetRS, leading the NCAA to be exclusively incorporated into
proteins from the pathogen and not the host. Because of these
features, BONCAT using NLL-MetRS is highly suited for analyz-
ing pathogen’s nascent protein expression at the host–patho-
gen interface. The potential of this approach was further
demonstrated in the interrogation of host–pathogen inter-
actions by infecting murine macrophages with E. coli that con-
stitutively expressed NLL-MetRS and visualizing the bacteria
selectively within the macrophage.
Using this cell selective BONCAT method, Mahdavi et al.
were able to enrich and identify several key secreted Yersinia
outer proteins (Yops) and other secreted factors in an infection
model.128 To enrich Yops that were secreted into the host
cytosol, HeLa cells were infected with NLL-MetRS-expressing
Yersinia cells and subsequently lysed using digitonin, preser-
Fig. 3 BONCAT probes for metabolic labeling of proteins.
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ving the integrity of the Yersinia cells. Subsequent reaction to
TAMRA-alkyne allowed for facile identification of fluorescent
Yops in host cytosol fractions. Moreover, by applying BONCAT
in a pulse-labeling manner at specific times after infections,
the authors were able to determine the order of Yop secretion,
demonstrating the potential of BONCAT for elucidating the
temporal aspects of virulence factor secretion. The Hang group
also reported a similar strategy for the labeling of intracellular
salmonella with 2-aminooctynoic acid (AOA, Fig. 3) and
showed that the bacterial proteome of Salmonella enterica
could be labeled and imaged with a high degree of selectivity
inside RAW-macrophages.129 In addition, this approach also
enabled for the enrichment and proteomic analysis of
endogenously expressed Salmonella proteins from infected
mammalian cells.
Amber codon suppression – the approach whereby a tRNA/
tRNA synthetase pair reactive to the amber stop codon are
introduced in a species have also been applied to the study of
pathogenic species. Wang et al. reported the application of
this strategy to incorporate para-iodophenylalanine into GFP
expressed in the Mtb-strain H37Ra inside RAW-macro-
phages.130 The same approach was later exploited by
Touchette et al. for the incorporation of the photo-crosslink-
able amino acid p-benzoyl-L-phenylalanine (pBPA, Fig. 3) into
the mycobacterial outer cell wall of M. smegmatis to identify
the interaction partners of this protein.131 It is likely that the
application of such techniques to study Mtb interactions with
the host proteome will deliver new insights. The expanded
genetic code variant of Salmonella was also recently reported
and used to incorporate p-azidophenylalanine (Fig. 3) into the
bacterial proteome. However, no intracellular labeling was
attempted yet by this approach.132 Intracellular labeling was
achieved for the facultative intracellular pathogen Neisseria
meningitides. Takahashi et al. also incorporated pBPA into the
bacterium and used it to elucidate the role of NMB1345 in the
infection pathway.133
ABPP CLEM of bacterial enzymes
A final area which is providing tantalizing new insights into
the intracellular biology of the host–pathogen interaction is
the use of probes to visualize the activity of specific pathogenic
enzymes inside the host, so-called activity-based protein profil-
ing (ABPP).134 This approach has been used to image host cell
alterations upon bacterial infection,135,136 but the imaging of
pathogenic enzymes – particularly those involved in virulence
– is an exciting new area.134 An early example involved the use
of the broad spectrum serine hydrolase probe FP-TAMRA
(Fig. 5) to identify the secreted serine hydrolases of Mtb137,138
and V. cholera.139 In a later study, all four V. cholera serine
hydrolases were identified using a proteomic approach in an
infection model of this pathogen. FP-TAMRA was also used to
identify 8 new serine hydrolases in the facultative140 intracellu-
lar pathogen Staphylococcus aureus.141 Lentz et al. used
FP-TAMRA to develop activity-based probes [ABPs] for two of
these hydrolases FphB and FphF. Using these inhibitors/
probes the authors could delineate a role for FphB in the infec-
tion of liver and heart cells, although an exact mechanism for
this role remains elusive. The recently resolved crystal struc-
ture of FphF in complex with the inhibitor may help in eluci-
dating these roles.142 Perhaps this relates to the potential for
Fig. 4 Correlative light-electron microscopy of triple labelled Mtb. Green: Alexa Fluor 488 alkyne reacted to Aha in the proteome; Red: Alexa Fluor
647 azide reacted to EDA; Pink: expressed DsRed signal. Grey: electron micrograph indicating the subcellular environment in which the bacteria
reside.
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intracellular survival of this pathogen under certain con-
ditions. Recently, the group of Bogyo also used this approach
to developed a covalent probe that allowed visualization of an
Mtb hydrolase, namely the hydrolase important for pathogen-
icity-1 (HIP-1). Using probe CSL173 (Fig. 5), they could observe
its activity when spiked into the host proteome to identify HIP-
activity.143 They have recently described the further develop-
ment of these types of probes to synthesize a chemilumines-
cent point-of-care test for Mtb that allowed the selective identi-
fication of live Mtb, providing a useful tool for the study of
drug efficacy.144
The electrophilic nature of the beta-lactam scaffold has also
been used to image penicillin binding protein (PBPs) activities
in pathogens.145 Initial approaches were marred by a poor sub-
strate specificity of these probes for the various PBPs. This was
recently solved for another facultative intracellular pathogen,
Streptococcus pneumoniae.146 By modifying the beta-lactam
core and attaching fluorescein (compound 7FL, Fig. 5) or
TAMRA to these modified lactam-cores, the PBPs 1b and 2×
could be selectively labeled and imaged in the dividing bac-
teria.147 With these probes it was found that these PBPs were
restricted to a ring surrounding the bacterial division site.
What these observations mean in the context of the recently
discovered intracellular niche of the pathogen remains to be
elucidated.
Conclusion
As these above examples clearly demonstrate, the application
of novel chemical approaches to imaging is leading to rapid
advances in the study of intracellular pathogens. The labeling
of cellular components and individual enzyme activities is
leading us to improved point of care tests.
There are, however, areas in which we foresee major devel-
opments taking place. An area, which will likely move the field
forward is the continuing development of better live-cell com-
patible chemistries. These will hopefully allow the develop-
ment of detailed dynamic pictures of the host–pathogen inter-
action. Reactions, such as the Inverse Electron-Demand Diels–
Alder ligation (IEDDA),148 can serve as excellent starting points
for this development. For the near future, we envisage that the
currently existing metabolic cell wall probes, D-alanine- and
trehalose analogues, will maintain their relevance, as there are
still many lingering questions concerning bacterial cell wall
metabolism and growth modes. Here we foresee that the use
of these methods, combined with advanced imaging and
quantification techniques, will be increasingly deployed to
study the efficacy of antibiotics in these host–pathogen inter-
actions. Information on the precise effects on the intracellular
live cycle of pathogens will increase understanding of the
method of actions of new and existing antibiotics.
Moreover, secreted bacterial proteins, many of which are
associated with virulence and persistence in the host environ-
ment, remain uncharacterized and their mechanisms of action
poorly understood; we envisage that BONCAT-probes can con-
tribute significantly to further the understanding of these
secreted factors through the use of new retrieval-mass spec-
trometry approaches. Together, these findings may lead to
novel vaccines, antibiotics and other therapies against bac-
terial infection.
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